Business
Result of Annual General Meeting
Allergy Therapeutics plc announced that all resolutions proposed at its 2026 Annual General Meeting were passed by shareholders, with overwhelming support for the approval of the 2025 accounts, directors' remuneration report, director elections and re-elections, auditor re-appointment, and authorities for share allotment. Specifically, Resolution 1, approving the 2025 Accounts, received 5,820,380,278 votes for, representing 99.99% of the votes cast, with 94.78% of the issued share capital participating. Similarly, resolutions concerning director appointments and share allotment authorities also saw very high percentages of approval, indicating strong shareholder confidence. Disclaimer*
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Group\")\n \nResult of Annual General Meeting\n \n \n29 January 2026 - Allergy Therapeutics plc (AIM:AGY), the fully commercial biotechnology company specialising in allergy immunotherapies, announces that all resolutions proposed at the 2026 Annual General Meeting (\"AGM\") held today were duly passed by shareholders on a show of hands.\n \nResolutions 1 to 10 (inclusive), were proposed as ordinary resolutions and resolutions 11 to 13 (inclusive) were proposed as special resolutions. The results of the proxy votes received ahead of the meeting are outlined in the table below.\n \n \n\n\n\n\nResolution\n\n\nFor:\n\n\n%\n\n\nAgainst:\n\n\n%\n\n\nTotal Votes Cast\n\n\n% of ISC\n\n\nWithheld\n\n\n\n\n1. Approval of 2025 Accounts\n\n\n5,820,380,278\n\n\n99.99%\n\n\n755,751\n\n\n0.01%\n\n\n5,821,136,029\n\n\n94.78%\n\n\n56,047\n\n\n\n\n2. Approval of Directors'\nRemuneration Report\n\n\n5,820,138,203\n\n\n99.99%\n\n\n836,062\n\n\n0.01%\n\n\n5,820,974,265\n\n\n94.78%\n\n\n217,811\n\n\n\n\n3. To elect Helge Weiner-Trapness as a Director\n\n\n5,818,973,760\n\n\n99.99%\n\n\n141,507\n\n\n0.01%\n\n\n5,819,115,267\n\n\n94.75%\n\n\n2,076,809\n\n\n\n\n4. To elect Lawrence Allen Wang as a Director\n\n\n5,818,962,852\n\n\n99.99%\n\n\n130,779\n\n\n0.01%\n\n\n5,819,093,631\n\n\n94.75%\n\n\n2,098,445\n\n\n\n\n5. To re-elect Tunde Otulana as a Director\n\n\n5,818,680,380\n\n\n99.99%\n\n\n418,353\n\n\n0.01%\n\n\n5,819,098,733\n\n\n94.75%\n\n\n2,093,343\n\n\n\n\n6. To re-elect Cheryl MacDiarmid as a Director\n\n\n5,818,939,949\n\n\n99.99%\n\n\n157,006\n\n\n0.01%\n\n\n5,819,096,955\n\n\n94.75%\n\n\n2,095,121\n\n\n\n\n7. To re-elect Peter Jensen O.B.E. as a Director\n\n\n5,804,855,547\n\n\n99.76%\n\n\n14,246,551\n\n\n0.24%\n\n\n5,819,102,098\n\n\n94.75%\n\n\n2,089,978\n\n\n\n\n8. To re-appoint BDO LLP as auditors of the Company\n\n\n5,818,732,937\n\n\n99.99%\n\n\n126,888\n\n\n0.01%\n\n\n5,818,859,825\n\n\n94.75%\n\n\n2,332,251\n\n\n\n\n9. To authorise the Directors to agree the auditors' remuneration\n\n\n5,820,969,519\n\n\n99.99%\n\n\n134,889\n\n\n0.01%\n\n\n5,821,104,408\n\n\n94.78%\n\n\n87,668\n\n\n\n\n10. Authority to allot shares\n\n\n5,820,919,431\n\n\n99.99%\n\n\n179,941\n\n\n0.01%\n\n\n5,821,099,372\n\n\n94.78%\n\n\n92,704\n\n\n\n\n11. Speci...